ATE222928T1 - Humanisierte antikörper gegen cd38 - Google Patents

Humanisierte antikörper gegen cd38

Info

Publication number
ATE222928T1
ATE222928T1 AT95937133T AT95937133T ATE222928T1 AT E222928 T1 ATE222928 T1 AT E222928T1 AT 95937133 T AT95937133 T AT 95937133T AT 95937133 T AT95937133 T AT 95937133T AT E222928 T1 ATE222928 T1 AT E222928T1
Authority
AT
Austria
Prior art keywords
antibody
sequence
framework region
cdrs
amino acid
Prior art date
Application number
AT95937133T
Other languages
English (en)
Inventor
Jonathan Henry Ellis
Alan Peter Lewis
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellcome Found filed Critical Wellcome Found
Application granted granted Critical
Publication of ATE222928T1 publication Critical patent/ATE222928T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT95937133T 1994-12-02 1995-11-28 Humanisierte antikörper gegen cd38 ATE222928T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9424449A GB9424449D0 (en) 1994-12-02 1994-12-02 Antibodies
PCT/GB1995/002777 WO1996016990A1 (en) 1994-12-02 1995-11-28 Humanized antibodies to cd38

Publications (1)

Publication Number Publication Date
ATE222928T1 true ATE222928T1 (de) 2002-09-15

Family

ID=10765384

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95937133T ATE222928T1 (de) 1994-12-02 1995-11-28 Humanisierte antikörper gegen cd38

Country Status (9)

Country Link
US (1) US20050158305A1 (de)
EP (1) EP0794966B1 (de)
JP (1) JPH10509876A (de)
AT (1) ATE222928T1 (de)
AU (1) AU3933695A (de)
DE (1) DE69527975T2 (de)
ES (1) ES2181795T3 (de)
GB (1) GB9424449D0 (de)
WO (1) WO1996016990A1 (de)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69920897T2 (de) 1998-04-28 2005-10-13 Smithkline Beecham Corp. Monoklonale antikörper mit verringerter immunisierungsfähigkeit
EP1174440A1 (de) * 2000-07-19 2002-01-23 U-BISys B.V. Ein selektiv exprimiertes Epitop auf das menschliches CD38 Molekül detektiert von einem "phage display library"-derivierten menschlichen scFv Antikörperfragment
CA2468733C (en) 2001-11-30 2013-06-11 Biogen Idec Ma Inc. Antibodies against monocyte chemotactic proteins
WO2004005351A2 (en) 2002-07-04 2004-01-15 Oncomab Gmbh Neoplasm specific antibodies and uses thereof
TWI323265B (en) 2002-08-06 2010-04-11 Glaxo Group Ltd Antibodies
DE10311248A1 (de) 2003-03-14 2004-09-30 Müller-Hermelink, Hans Konrad, Prof. Dr. Humaner monoklonaler Antikörper
GB0306309D0 (en) 2003-03-19 2003-04-23 Glaxo Group Ltd Method of treatment
EP1531162A1 (de) 2003-11-14 2005-05-18 Heinz Vollmers Antikörper SAM-6, der spezifisch von Adenocarzinom ist, und dessen Verwendungen
DE10353175A1 (de) 2003-11-14 2005-06-16 Müller-Hermelink, Hans Konrad, Prof. Dr. Humaner monoklonaler Antikörper mit fettsenkender Wirkung
US9200061B2 (en) 2004-02-06 2015-12-01 Morpho Sys AG Generation and profiling of fully human HuCAL gold®-derived therapeutic antibodies specific for human CD3i
ES2541489T3 (es) * 2004-02-06 2015-07-21 Morphosys Ag Anticuerpos humanos anti-CD38 y usos para ellos
AU2005235811B2 (en) 2004-02-06 2011-11-03 Morphosys Ag Anti-CD38 human antibodies and uses therefor
CN112480257A (zh) * 2005-03-23 2021-03-12 根马布股份公司 用于治疗多发性骨髓瘤的cd38抗体
AR053489A1 (es) * 2005-05-24 2007-05-09 Morphosys Ag Generacion perfilado de anticuerpos terapeuticos totalmente derivados de hucal gold humanos especificos para cd38 humano
CA2611778C (en) 2005-06-20 2012-11-27 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
USRE47223E1 (en) 2005-06-20 2019-02-05 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
BRPI0618399B1 (pt) 2005-10-12 2023-10-03 Morphosys Ag Anticorpo específico anti-cd38 humano, composição de ácido nucleico, vetor de expressão, composição farmacêutica, uso do anticorpo e uso de uma composição farmacêutica
GB0525662D0 (en) 2005-12-16 2006-01-25 Glaxo Group Ltd Immunoglobulins
US20100267145A1 (en) * 2006-06-05 2010-10-21 Hiroshima University Immunocompetent cell having anti-cd38 antibody on its cell surface
DK2081595T3 (da) 2006-09-26 2019-07-15 Genmab As Anti-cd38 plus corticosteroid plus et ikke-corticosteroid kemoterapeutikum til behandling af tumorer
EP1914242A1 (de) * 2006-10-19 2008-04-23 Sanofi-Aventis Neue Antikörper gegen CD38 zur Behandlung von Krebs
EP2144628B1 (de) 2007-05-08 2012-10-17 Genentech, Inc. Cystein-manipulierte anti-muc16-antikörper und antikörper-wirkstoff-konjugate
EA023031B1 (ru) 2007-11-30 2016-04-29 Глаксо Груп Лимитед Антиген-связывающая конструкция и ее применение
WO2010097394A1 (en) 2009-02-24 2010-09-02 Glaxo Group Limited Multivalent and/or multispecific rankl-binding constructs
CA2753332A1 (en) 2009-02-24 2010-09-02 Glaxo Group Limited Antigen-binding constructs
US20110305692A1 (en) 2009-02-24 2011-12-15 Glaxo Group Limited Antigen-binding contructs
CA2757237A1 (en) 2009-04-01 2010-10-14 Jane Elizabeth Clarkson Anti-il-23 immunoglobulins
EP2421611A1 (de) 2009-04-24 2012-02-29 Glaxo Group Limited Fgfr1c-antikörper-kombinationen
SI2580243T1 (sl) 2010-06-09 2020-02-28 Genmab A/S Protitelesa proti humanemu CD38
TR201810773T4 (tr) 2010-11-23 2018-08-27 Glaxo Group Ltd Onkostatin m?ye (osm) antijen bağlayıcı proteinler.
EP2853542A1 (de) 2010-11-24 2015-04-01 Glaxo Group Limited Auf HGF abzielende multispezifische antigenbindende Proteine
US8974782B2 (en) 2011-02-07 2015-03-10 Glaxo Group Limited Treatment of stroke comprising anti-MAG antibodies
EA028220B1 (ru) 2011-05-27 2017-10-31 Глаксо Груп Лимитед Иммуноконъюгат на основе белка, связывающегося с bcma (cd269/tnfrsf17), его медицинское применение и фармацевтическая композиция
EP2888279A1 (de) 2012-08-22 2015-07-01 Glaxo Group Limited Anti-lrp6-antikörper
GB201216002D0 (en) 2012-09-07 2012-10-24 Deutsches Rheuma Forschungszentrum Berlin Drfz Compositions adn methods
MA38498B1 (fr) 2013-03-15 2018-11-30 Glaxosmithkline Ip Dev Ltd Protéines de liaison anti-lag-3
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
NZ729816A (en) 2014-09-09 2024-08-30 Janssen Biotech Inc Combination therapies with anti-cd38 antibodies
KR102597989B1 (ko) 2014-12-04 2023-11-02 얀센 바이오테크 인코포레이티드 급성 골수성 백혈병을 치료하기 위한 항-cd38 항체
EP4219561A3 (de) 2015-05-20 2023-11-08 Janssen Biotech, Inc. Anti-cd38-antikörper zur behandlung von leichtkettiger amyloidose und anderen cd38-positiven hämatologischen malignomen
PL3303373T3 (pl) 2015-05-30 2020-09-21 Molecular Templates, Inc. Deimmunizowane rusztowania podjednostki a toksyny shiga oraz zawierające je cząsteczki nakierowane na komórki
CN107708734B (zh) 2015-06-22 2022-01-11 詹森生物科技公司 用抗cd38抗体和生存素抑制剂联合治疗血红素恶性肿瘤
US20170044265A1 (en) 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
EP3798234A1 (de) 2015-09-02 2021-03-31 Immutep S.A.S. Agonistische anti-lag-3 antikörper
SI3827845T1 (sl) 2015-11-03 2022-06-30 Janssen Biotech, Inc. Subkutane formulacije protiteles proti CD38 in njihove uporabe
US10781261B2 (en) 2015-11-03 2020-09-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
WO2019089832A1 (en) 2017-10-31 2019-05-09 Janssen Biotech, Inc. Methods of treating high risk multiple myeloma
AU2020308053A1 (en) 2019-06-26 2022-01-20 Glaxosmithkline Intellectual Property Development Limited IL1RAP binding proteins
US20220372098A1 (en) * 2019-06-26 2022-11-24 The Johns Hopkins University Methods and materials for targeted expansion of immune effector cells
US20220257796A1 (en) 2019-07-02 2022-08-18 Fred Hutchinson Cancer Research Center Recombinant ad35 vectors and related gene therapy improvements
JP2023530675A (ja) * 2020-06-17 2023-07-19 ワイ－マブス セラピューティクス， インコーポレイテッド ヒト疾患の治療のためのｃｄ３８抗体
WO2022169825A1 (en) 2021-02-03 2022-08-11 Mozart Therapeutics, Inc. Binding agents and methods of using the same
WO2023076876A1 (en) 2021-10-26 2023-05-04 Mozart Therapeutics, Inc. Modulation of immune responses to viral vectors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
GB9022543D0 (en) * 1990-10-17 1990-11-28 Wellcome Found Antibody production
GB9221654D0 (en) * 1992-10-15 1992-11-25 Scotgen Ltd Recombinant human anti-cytomegalovirus antibodies
CA2128544A1 (en) * 1992-12-10 1994-06-23 Celltech Therapeutics Limited Humanised antibodies directed against a33 antigen
WO1994017184A1 (en) * 1993-01-29 1994-08-04 Schering Corporation Modulation of physiological responses of lymphocytes by cd38 or antibodies thereto

Also Published As

Publication number Publication date
WO1996016990A1 (en) 1996-06-06
EP0794966B1 (de) 2002-08-28
DE69527975D1 (de) 2002-10-02
AU3933695A (en) 1996-06-19
EP0794966A1 (de) 1997-09-17
US20050158305A1 (en) 2005-07-21
GB9424449D0 (en) 1995-01-18
JPH10509876A (ja) 1998-09-29
DE69527975T2 (de) 2003-03-27
ES2181795T3 (es) 2003-03-01

Similar Documents

Publication Publication Date Title
ATE222928T1 (de) Humanisierte antikörper gegen cd38
BRPI0413489A (pt) composições polipeptìdicas de ligação a cd20
MXPA05003621A (es) Metodos de tratamiento de la enfermedad de alzheimer usando anticuerpos dirigidos contra el peptido beta amiloide y composiciones de los mismos.
UA29494C2 (uk) Гуманізовані антитіла, способи їх продукування, спосіб лікування хвороби крона, спосіб лікування розсіяного склерозу, фармацевтична композиція
DE69429095D1 (de) Humanisierte antikoerper
NZ324500A (en) Humanized antibodies to human gp39, compositions containing and therapeutic use thereof
CA2501984A1 (en) Erythropoietin receptor binding antibodies
TR200202254T2 (tr) IL-18 Kaynaklı rahatsızlıkların tedavisinde faydalı rekombinant IL-18 antagonistleri.
NZ529571A (en) Human antibodies that bind human IL-12 and methods for producing
GR3026219T3 (en) Mouse monoclonal antibodies
DE69535319D1 (de) Rekombinante il-5 antagonisten für die behandlung von il-5 bedingten krankheiten
DE69426767D1 (de) Anti idiotypische Antikörper gegen Gonococcen und diese verwendende Verfahren und Zusammensetzungen.
DE69125485D1 (de) Verfahren und zwischenprodukte synthetischer antikörperderivate
ATE285418T1 (de) Humanisierter antikörper spezifisch für das oberflächenantigen pre-s1 von hbv und dessen präparation
DK0493446T3 (da) Behandling af autoimmunsygdom.
EP0725081A4 (de) MONOKLONALER ANTIKÖRPER GEGEN MxA DES MENSCHLICHEN Mx PROTEINS
FI20095269A (fi) Lymfosyyttien sitoutumiseen vaikuttava ihmisen endoteelisolun molekyyli
FR2571146B1 (fr) Antigenes carcino-foetaux du pancreas humain et un procede de purification, antiserum contre ces antigenes et son procede de preparation et compositions diagnostiques les contenant
HUP0301085A2 (hu) Új peptid és alkalmazása szelektálási eljárásra
WO2023004036A3 (en) Anti-fsh antibodies for neurodegenerative diseases

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties